Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...
10don MSN
Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...
OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the ...
ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Jumpcode Genomics ('Jumpcode'), a life science tools company ...
The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.
In a decision filed March 28, Hon. Steven C. Seeger granted The Lansing Journal’s motion to dismiss the lawsuit filed by Lan-Oak Park District ...
NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn ...
Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results